HC Wainwright Reiterates Buy Rating on Conexeu Sciences
HC Wainwright maintains a buy rating for Conexeu Sciences, setting a $20 price target, a 87.09% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on Conexeu Sciences (CNXU) with a $20 price target on June 22, 2026.
- HC Wainwright's $20 price target implies 87.09% upside from Conexeu Sciences Inc.'s ($CNXU) current $10.69 share price.
- Shares of CNXU traded at $13.28 on Tuesday, with a market cap of about $325.9 million and a 52-week range of $9.60 to $18.79.
- Conexeu Sciences, a biotech firm focused on regenerative tissue products, remains a focus of analyst attention with a reiterated buy rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its buy rating on Conexeu Sciences Inc. (NasdaqCM:CNXU), maintaining a price target of $20. The rating and target were confirmed on June 22, 2026, by analyst Swayampakula Ramakanth.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Conexeu Sciences Inc. Stock Up 51.2%
Shares of NasdaqCM:CNXU traded near $13.28 on Tuesday. Conexeu Sciences Inc. has a market cap of approximately $325.9 million. The stock has seen a 52-week low of $9.60 and a high of $18.79. It has a 50-day moving average of $13.58, matching its 200-day moving average. The company's financial health is highlighted by a strong current ratio of 8.512 and a quick ratio of 7.139, with a low debt-to-equity ratio of 0.055.
$CNXU price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
About Conexeu Sciences
Conexeu Sciences Inc., based in Reno, Nevada, operates in the healthcare sector, specifically within biotechnology. The company develops collagen-based regenerative tissue scaffold products used in medical aesthetics and tissue repair. Its offerings include a patented collagen extracellular matrix scaffold platform for various applications like wound care and facial rejuvenation. Founded in 2022, Conexeu is led by CEO Mr. Miles D. Harrison and focuses on innovative solutions for the beauty, aesthetics, and medical sectors.
Bottom Line
HC Wainwright's reiteration of a buy rating with a $20 target underscores continued interest in Conexeu Sciences. The biotech firm, known for its regenerative tissue products, remains a notable player in the healthcare sector. Investors keep an eye on such analyst ratings as part of their broader strategy, though it's important to note that these are backward-looking assessments.
Get Conexeu Sciences Inc. alerts
New 13F filings, insider trades, and analyst moves on $CNXU, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.